FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120123122> ?p ?o ?g. }

• W3120123122 endingPage "S753" @default.
• W3120123122 startingPage "S752" @default.
• W3120123122 abstract "Abstract Background Despite nearly universal influenza vaccination for active duty military personnel, breakthrough influenza infections occur. We are reporting on the second year of the Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED), comparing three FDA-licensed influenza vaccine types (egg-based, cell -based, and recombinant) to assess differences in immunogenicity and effectiveness. Methods Participants in the second year of PAIVED were enrolled from Oct 2019 through Jan 2020 at 9 military facilities. Participants received weekly inquiries about influenza-like-illnesses (ILI) experienced in the past week, and if the participant reported having a cough or sore throat and a) muscle/body aches or fatigue and/or b) being feverish or having chills, they were scheduled for a clinic visit. During this visit, a blood sample and a nasal swab were collected, as well as information about symptom duration and severity. A second (convalescent) visit was conducted approximately 4 weeks later, which involved collecting additional information about the duration of symptoms and illness burden, as well as a second blood draw. Due to the COVID-19 pandemic, acute and convalescent visits were disrupted at most sites in March and April due to COVID-19 precautions. Results PAIVED year 2 enrolled 5,892 participants who completed demographic forms (Table 1). Among those who reported any ILIs, most reported one ILI (1,345), while 264 reported two ILIs, and 42 reported three ILIs. Nasal swabs were processed from 273 ILIs at four sites (Fig 1), and 14 cases of influenza were identified thus far. The median duration of ILIs was ten days, with a median of three days of limited activity, and two days with fever. Nine individuals were hospitalized. Table 1. Demographic characteristics of individuals enrolled in PAIVED 2019/20 Figure 1. Lab results as of 5/15 (N=273 samples) Conclusion Over 25% of participants reported an ILI, and 5% of the nasal swabs that have been tested thus far have been positive for influenza. While most samples have not yet been analyzed, we have identified some breakthrough cases of influenza among vaccinated participants. Planned analyses include comparative vaccine effectiveness in order to inform future vaccine purchasing decisions. Disclaimer Disclosures All Authors: No reported disclosures" @default.
• W3120123122 created "2021-01-18" @default.
• W3120123122 creator A5000166462 @default.
• W3120123122 creator A5003637667 @default.
• W3120123122 creator A5004447215 @default.
• W3120123122 creator A5007293184 @default.
• W3120123122 creator A5007853642 @default.
• W3120123122 creator A5009912008 @default.
• W3120123122 creator A5010496694 @default.
• W3120123122 creator A5010911816 @default.
• W3120123122 creator A5015331279 @default.
• W3120123122 creator A5016999436 @default.
• W3120123122 creator A5038658646 @default.
• W3120123122 creator A5043112234 @default.
• W3120123122 creator A5044388477 @default.
• W3120123122 creator A5045370912 @default.
• W3120123122 creator A5051751609 @default.
• W3120123122 creator A5059536572 @default.
• W3120123122 creator A5059548038 @default.
• W3120123122 creator A5061645534 @default.
• W3120123122 creator A5078188326 @default.
• W3120123122 creator A5086592075 @default.
• W3120123122 creator A5088594495 @default.
• W3120123122 date "2020-10-01" @default.
• W3120123122 modified "2023-10-16" @default.
• W3120123122 title "1501. Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED): Updates from Year 2 of multi-site trial" @default.
• W3120123122 doi "https://doi.org/10.1093/ofid/ofaa439.1682" @default.
• W3120123122 hasPublicationYear "2020" @default.
• W3120123122 type Work @default.
• W3120123122 sameAs 3120123122 @default.
• W3120123122 citedByCount "0" @default.
• W3120123122 crossrefType "journal-article" @default.
• W3120123122 hasAuthorship W3120123122A5000166462 @default.
• W3120123122 hasAuthorship W3120123122A5003637667 @default.
• W3120123122 hasAuthorship W3120123122A5004447215 @default.
• W3120123122 hasAuthorship W3120123122A5007293184 @default.
• W3120123122 hasAuthorship W3120123122A5007853642 @default.
• W3120123122 hasAuthorship W3120123122A5009912008 @default.
• W3120123122 hasAuthorship W3120123122A5010496694 @default.
• W3120123122 hasAuthorship W3120123122A5010911816 @default.
• W3120123122 hasAuthorship W3120123122A5015331279 @default.
• W3120123122 hasAuthorship W3120123122A5016999436 @default.
• W3120123122 hasAuthorship W3120123122A5038658646 @default.
• W3120123122 hasAuthorship W3120123122A5043112234 @default.
• W3120123122 hasAuthorship W3120123122A5044388477 @default.
• W3120123122 hasAuthorship W3120123122A5045370912 @default.
• W3120123122 hasAuthorship W3120123122A5051751609 @default.
• W3120123122 hasAuthorship W3120123122A5059536572 @default.
• W3120123122 hasAuthorship W3120123122A5059548038 @default.
• W3120123122 hasAuthorship W3120123122A5061645534 @default.
• W3120123122 hasAuthorship W3120123122A5078188326 @default.
• W3120123122 hasAuthorship W3120123122A5086592075 @default.
• W3120123122 hasAuthorship W3120123122A5088594495 @default.
• W3120123122 hasBestOaLocation W31201231221 @default.
• W3120123122 hasConcept C126322002 @default.
• W3120123122 hasConcept C141071460 @default.
• W3120123122 hasConcept C187212893 @default.
• W3120123122 hasConcept C194828623 @default.
• W3120123122 hasConcept C203014093 @default.
• W3120123122 hasConcept C22070199 @default.
• W3120123122 hasConcept C2522874641 @default.
• W3120123122 hasConcept C2777870961 @default.
• W3120123122 hasConcept C2778594517 @default.
• W3120123122 hasConcept C2779134260 @default.
• W3120123122 hasConcept C2779954635 @default.
• W3120123122 hasConcept C2780689484 @default.
• W3120123122 hasConcept C3008058167 @default.
• W3120123122 hasConcept C524204448 @default.
• W3120123122 hasConcept C71924100 @default.
• W3120123122 hasConcept C89623803 @default.
• W3120123122 hasConceptScore W3120123122C126322002 @default.
• W3120123122 hasConceptScore W3120123122C141071460 @default.
• W3120123122 hasConceptScore W3120123122C187212893 @default.
• W3120123122 hasConceptScore W3120123122C194828623 @default.
• W3120123122 hasConceptScore W3120123122C203014093 @default.
• W3120123122 hasConceptScore W3120123122C22070199 @default.
• W3120123122 hasConceptScore W3120123122C2522874641 @default.
• W3120123122 hasConceptScore W3120123122C2777870961 @default.
• W3120123122 hasConceptScore W3120123122C2778594517 @default.
• W3120123122 hasConceptScore W3120123122C2779134260 @default.
• W3120123122 hasConceptScore W3120123122C2779954635 @default.
• W3120123122 hasConceptScore W3120123122C2780689484 @default.
• W3120123122 hasConceptScore W3120123122C3008058167 @default.
• W3120123122 hasConceptScore W3120123122C524204448 @default.
• W3120123122 hasConceptScore W3120123122C71924100 @default.
• W3120123122 hasConceptScore W3120123122C89623803 @default.
• W3120123122 hasIssue "Supplement_1" @default.
• W3120123122 hasLocation W31201231221 @default.
• W3120123122 hasLocation W31201231222 @default.
• W3120123122 hasLocation W31201231223 @default.
• W3120123122 hasOpenAccess W3120123122 @default.
• W3120123122 hasPrimaryLocation W31201231221 @default.
• W3120123122 hasRelatedWork W1984349242 @default.
• W3120123122 hasRelatedWork W1999148014 @default.
• W3120123122 hasRelatedWork W1999679084 @default.
• W3120123122 hasRelatedWork W2047565563 @default.
• W3120123122 hasRelatedWork W2163737296 @default.
• W3120123122 hasRelatedWork W2520368858 @default.

• next